57 days.
That's how long it took the world to go from declaring an emergency to injecting the first human.
No, this isn't a movie script.
This is Ebola. And this time, the response is scary fast.
Here's the backdrop you need first.
A new Ebola outbreak — caused by the Bundibugyo strain — is tearing through the Democratic Republic of Congo and Uganda.
1,561 confirmed cases.
506 deaths.
The third-largest Ebola outbreak ever recorded.
WHO called it a Public Health Emergency of International Concern on May 17.
And until now… there was no vaccine built specifically for this strain.
Oxford's Pandemic Sciences Institute just pushed a brand-new vaccine candidate into Phase 1 human trials.
50 healthy volunteers. Age 18-55. Right there in the UK.
It's the first-ever vaccine to specifically target Bundibugyo Ebola to reach this stage.
And it's riding on a platform you already trust — the same ChAdOx viral vector tech behind the Oxford-AstraZeneca Covid vaccine.
That one is estimated to have saved 6 million+ lives in its first year alone.
While Oxford designs it, someone still has to make it. Fast.
That's where Pune's Serum Institute of India stepped in.
🏭 Manufactured 620,000 emergency doses — in just two weeks
💊 Supplied 4,000 doses for the trial itself
💰 Backed by an $8.6 million fast-track partnership with CEPI and Oxford
Adar Poonawalla's line says it all: "speed, preparedness and global collaboration."
This isn't charity. It's India quietly becoming the world's emergency pharmacy.
Most vaccines take years to reach a single human arm.
This one did it in under two months from emergency declaration.
Next stop: additional trials in Uganda itself, where the virus is actively spreading.
Somewhere between a lab in Oxford and a factory floor in Pune…
a race against a virus just got a serious head start.
And 620,000 doses are already sitting there, waiting to be needed.
That's all for now!
